# Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

> **NCT00050596** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** MDX-010 / MDX-010 + Docetaxel

## Key facts

- **NCT ID:** NCT00050596
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** — (—)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050596, "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00050596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*